Literature DB >> 10622066

A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice.

R Jones1, C Tait, G Sladen, J Weston-Baker.   

Abstract

Computer models of different strategies for the management of dyspepsia in primary care indicate that a 'test-and-treat' approach is likely to be associated with the lowest costs and acceptable clinical outcomes. We present information on computer modelling studies and report the findings of a randomised trial comparing a Helicobacter pylori test-and-treat strategy with referral to direct access endoscopy in the management of dyspepsia in general practice. We compared costs and clinical outcomes in patients managed for one year in study (test-and-treat) and control (endoscopy) practices in south London. Patients aged less than 45 years presenting with persistent dyspepsia without alarm symptoms (141 study patients, 91 control patients) were studied. In the one-year follow-up period there were 17 endoscopies in the study group: all the control patients underwent initial endoscopy and five further endoscopies were performed. None revealed peptic ulcer or cancer. Forty-three (30%) of the study patients compared with 16 (17%) of the controls were referred to hospital clinics (p < 0.025). The cost of management per patient for one year in the study group was 205.67 Pounds, compared with 404.31 Pounds in the control group (p < 0.0001). Clinical outcomes in both groups at one year were comparable. An H. pylori test-and-treat strategy for dyspeptic patients aged less than 45, employing office-based serology testing, appears to be associated with substantially lower costs than initial endoscopy and with similar clinical outcomes.

Entities:  

Mesh:

Year:  1999        PMID: 10622066

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  15 in total

1.  H. Pylori testing and endoscopy for dyspepsia in primary care. Improved diagnostic accuracy is important in dyspepsia.

Authors:  V Heatley
Journal:  BMJ       Date:  2001-08-11

Review 2.  Approaches to uninvestigated dyspepsia.

Authors:  R H Jones
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

3.  Limited impact on endoscopy demand from a primary care based 'test and treat' dyspepsia management strategy: the results of a randomised controlled trial.

Authors:  Ian S Shaw; Roland M Valori; André Charlett; Cliodna A M McNulty
Journal:  Br J Gen Pract       Date:  2006-05       Impact factor: 5.386

Review 4.  A systematic review of the effect of primary care-based service innovations on quality and patterns of referral to specialist secondary care.

Authors:  Alex Faulkner; Nicola Mills; David Bainton; Kate Baxter; Paul Kinnersley; Tim J Peters; Deborah Sharp
Journal:  Br J Gen Pract       Date:  2003-11       Impact factor: 5.386

5.  Noninvasive tests to diagnose Helicobacter pylori infection.

Authors:  Luigi Gatta; Chiara Ricci; Andrea Tampieri
Journal:  Curr Gastroenterol Rep       Date:  2003-10

Review 6.  Best practice in primary care pathology: review 1.

Authors:  W S A Smellie; D Wilson; C A M McNulty; M J Galloway; G A Spickett; D I Finnigan; D A Bareford; M A Greig; J Richards
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

7.  Testing for Helicobacter pylori in dyspeptic patients suspected of peptic ulcer disease in primary care: cross sectional study.

Authors:  C F Weijnen; M E Numans; N J de Wit; A J Smout; K G Moons; T J Verheij; A W Hoes
Journal:  BMJ       Date:  2001-07-14

Review 8.  Helicobacter pylori test and treat strategy for young dyspeptic patients: new data.

Authors:  P Moayyedi
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 9.  Management of uninvestigated dyspepsia: review and commentary.

Authors:  Anthony Axon
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

10.  Helicobacter pylori Eradication Therapy in Nonulcer Dyspepsia is Beneficial.

Authors:  Mohammed Q Khan
Journal:  Saudi J Gastroenterol       Date:  2008-04       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.